Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cosentyx Generic Name & Formulations
Legal Class
Rx
General Description
Secukinumab 75mg/0.5mL, 150mg/mL; soln for SC inj; 150mg/vial; lyophilized pwd for SC inj after reconstitution; preservative-free.
Pharmacological Class
Interleukin-17A antagonist.
How Supplied
Single-dose Sensoready pen (150mg)—1, 2; Single-dose prefilled syringe (150mg)—1, 2; (75mg)—1; Single-dose vial—1
Manufacturer
Generic Availability
NO
Cosentyx Indications
Indications
Active psoriatic arthritis (PsA) in patients aged ≥2yrs. Active enthesitis-related arthritis (ERA) in patients aged ≥4yrs. Active ankylosing spondylitis (AS) in adults. Active non-radiographic axial spondyloarthritis (nraxSpA) in adults with objective signs of inflammation.
Cosentyx Dosage and Administration
Adult
Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: PsA with coexistent plaque psoriasis: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. Other PsA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks. Consider 300mg every 4 weeks if PsA continues. Cosentyx may be administered with or without MTX. AS (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks. Consider 300mg every 4 weeks if AS continues. nraxSpA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks.
Children
AS or nraxSpA (<18yrs): not established. PsA (<2yrs or <15kg) or ERA (<4yrs or <15kg): not established. PsA (≥2yrs): ≥15–<50kg: 75mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; ≥50kg: 150mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Cosentyx may be administered with or without MTX. ERA (≥4yrs): ≥15–<50kg: 75mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; ≥50kg: 150mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
Cosentyx Contraindications
Not Applicable
Cosentyx Boxed Warnings
Not Applicable
Cosentyx Warnings/Precautions
Warnings/Precautions
May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Complete all immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.
Cosentyx Pharmacokinetics
See Literature
Cosentyx Interactions
Interactions
Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.
Cosentyx Adverse Reactions
Adverse Reactions
Nasopharyngitis, diarrhea, upper respiratory tract infection; inflammatory bowel disease, hypersensitivity reactions, other serious infections.
Cosentyx Clinical Trials
See Literature
Cosentyx Note
Not Applicable
Cosentyx Patient Counseling
See Literature
Cosentyx Generic Name & Formulations
Legal Class
Rx
General Description
Secukinumab 75mg/0.5mL, 150mg/mL; soln for SC inj; 150mg/vial; lyophilized pwd for SC inj after reconstitution; preservative-free.
Pharmacological Class
Interleukin-17A antagonist.
How Supplied
Single-dose Sensoready pen (150mg)—1, 2; Single-dose prefilled syringe (150mg)—1, 2; (75mg)—1; Single-dose vial—1
Manufacturer
Generic Availability
NO
Cosentyx Indications
Indications
Moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.
Cosentyx Dosage and Administration
Adult
Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. For some patients, 150mg dose may be acceptable.
Children
<6yrs: not established. Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). Give by SC inj at Weeks 0, 1, 2, 3, and 4 then every 4 weeks thereafter. ≥6yrs (<50kg): 75mg; (≥50kg): 150mg.
Cosentyx Contraindications
Not Applicable
Cosentyx Boxed Warnings
Not Applicable
Cosentyx Warnings/Precautions
Warnings/Precautions
May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Complete all immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.
Cosentyx Pharmacokinetics
See Literature
Cosentyx Interactions
Interactions
Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.
Cosentyx Adverse Reactions
Adverse Reactions
Nasopharyngitis, diarrhea, upper respiratory tract infection; inflammatory bowel disease, hypersensitivity reactions, other serious infections.
Cosentyx Clinical Trials
See Literature
Cosentyx Note
Not Applicable
Cosentyx Patient Counseling
See Literature
Images
